LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO)

Author
Tran, N.
Ozguroglu, M.
Sulur, G.
Protheroe, A.
Li, S.
Mundle, S. D.
Chi, K. N.
Rodriguez Antolin, A.
Feyerabend, S.
Fein, L.
Alekseev, B. Y.
De Porre, P.
Matsubara, N.
Fazazi, K.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/122369
Collections